dr. daniel petrylak on the role of enzalutamide in prostate cancer
Published 11 years ago • 1K plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:18
dr. petrylak on the role of psa screening in prostate cancer
-
0:47
dr. daniel petrylak describes the clinical investigation of prostvac in prostate cancer
-
1:10
dr. daniel petrylak discusses chemotherapy in prostate cancer
-
0:47
dr. petrylak on the recent developments in prostate cancer
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
1:02
dr. petrylak on the stride study: concurrent vs sequential enzalutamide with sipuleucel-t for mcrpc
-
1:28:53
hormones and cancer: separating fact from fiction with dr. peter fotinos
-
1:11
dr. daniel petrylak on sipuleucel-t delaying time to first opioid use
-
1:43
dr. petrylak on imaging approaches in prostate cancer
-
1:08
dr. daniel petrylak explains the correlation between immune response to sipuleucel-t and survival
-
0:39
daniel petrylak, md, on the current role of ctc tumor cell components via liquid biopsy pc treatment
-
1:21
dr. petrylak explains prostate cancer clinical trial difficulties
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
2:37
dr. daniel petrylak discusses novel bone targeted therapies in prostate cancer
-
0:57
daniel petrylak, md, on prostate cancer guidelines and the results of the latitude study
-
8:47
treatment of metastatic crpc
-
0:34
daniel petrylak, md, explains the effect of second antigen spread in mcrpc patients
-
0:34
dr. petrylak discusses custirsen as a potential treatment for prostate cancer